CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 159 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2014. The put-call ratio across all filers is 1.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $17,928,000 | +1160.8% | 7,694,417 | +1437.1% | 0.01% | +700.0% |
Q4 2017 | $1,422,000 | +12.6% | 500,576 | +13.4% | 0.00% | 0.0% |
Q3 2017 | $1,263,000 | +33.9% | 441,411 | +15.6% | 0.00% | – |
Q2 2017 | $943,000 | -75.2% | 381,782 | +57.3% | 0.00% | -100.0% |
Q4 2015 | $3,807,000 | +64.4% | 242,780 | +10.5% | 0.00% | +100.0% |
Q3 2015 | $2,316,000 | -70.1% | 219,710 | -28.5% | 0.00% | -75.0% |
Q2 2015 | $7,750,000 | +13.9% | 307,263 | +25.9% | 0.00% | 0.0% |
Q1 2015 | $6,802,000 | +336.6% | 244,061 | +186.0% | 0.00% | +300.0% |
Q4 2014 | $1,558,000 | +157.5% | 85,348 | +82.7% | 0.00% | – |
Q3 2014 | $605,000 | -36.2% | 46,715 | -19.6% | 0.00% | -100.0% |
Q2 2014 | $948,000 | -84.9% | 58,130 | -83.7% | 0.00% | -75.0% |
Q1 2014 | $6,288,000 | -54.7% | 355,785 | -38.0% | 0.00% | -50.0% |
Q4 2013 | $13,895,000 | -0.7% | 573,933 | +45.3% | 0.01% | -11.1% |
Q3 2013 | $13,990,000 | +1044.8% | 394,863 | +404.7% | 0.01% | +800.0% |
Q2 2013 | $1,222,000 | – | 78,236 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
Bellevue Group AG | 160,000 | $646,000 | 0.12% |
PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |